Global Autoinjectors Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 - 2030

Global Autoinjectors Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 - 2030

Global Autoinjectors Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 – 2030

Global Autoinjectors Market was valued US$ 56.5 Billion in 2022 and is expected to reach ~US$ 410 Billion by 2032, growing at a CAGR of 22.1% during the forecast period 2023-2032.

A syringe with a spring-loaded needle and a predetermined amount of medication is called an auto-injector. It releases and gives a precisely calibrated dose of the medication when pushed in a sliding motion on the body. Among the many advantages of auto-injectors are the reduction of needle-related disorders and phobias as well as the decreased chance of needle stick incidents. Auto-injectors are useful for self-administering adrenaline to avoid anaphylaxis, giving migraine patients rapid relief, and supporting a range of medical and emergency procedures. The need for auto-injectors is rising due to the rising prevalence of anaphylaxis.

Auto-injectors are becoming more and more popular than conventional devices because of their capacity to improve drug delivery efficiency and accept novel formulations. Technological developments in this product category are anticipated to propel market expansion. The Humira product from AbbVie, Inc., for example, has features like injection starts and end notifications and a locking function that demonstrate the promise of technological innovation in auto-injectors. Numerous advantages come with auto-injectors, such as less anxiety associated with needles, decreased danger of needle stick injuries, reliable dose precision, and enhanced overall efficacy. Auto-injectors offer more regulated medicine delivery than manual injections. The features of the medicine usually dictate the injection site selection, with intramuscular administration being the most common option. The fact that auto-injectors are more comfortable than conventional syringes is another factor in their rising popularity. But the availability of other forms, including oral pills, might prevent the industry from expanding.

It is anticipated that the addition of novel device features would accelerate growth even more. As an illustration, Bayer HealthCare introduced an electronic auto-injector for the management of relapsing-remitting multiple sclerosis in September 2015. By providing accurate medication dosages, this gadget encourages patient compliance and may lower total treatment expenses. A range of auto-injectors made to handle high viscosity and big volume medications is available from the SHL group.

Autoinjectors have a number of advantages, such as quick medicine delivery and ease of use. Critical situations that call for quick medical attention include anaphylactic shocks and opiate overdoses. Food allergies, insect stings, and medication allergies are common causes of anaphylactic shocks, which can be fatal if left untreated. Anaphylaxis has always been treated mostly with epinephrine. Portable and quick to administer, epinephrine autoinjectors are especially helpful for people who have experienced anaphylactic crises in the past. As such, autoinjectors are essential for treating illnesses that require immediate medical treatment. It is projected that the benefits offered by autoinjectors would support market expansion.

“Reusable segment, by usage, to be largest market from 2023 to 2030.”

The usage segment of the global autoinjectors market comprise of reusable and disposable segment. These submarkets within the larger self-injection device market are distinguished by their features, functions, and designs. Because they are made to last for several uses, reusable autoinjectors usually enable patients to deliver multiple doses of medication before needing to be replaced or refilled. Refillable cartridges or reservoirs that can hold medication for multiple uses are frequently included with them. Single-use disposable autoinjectors are made for use just once. The entire device is thrown away after the drug has been utilised. These are usually discarded of after usage and pre-filled with a predetermined dosage of medication.

“Manual segment, by technology, to be largest market from 2023 to 2030.”

The autoinjectors market is categorized into two key segments based on their technology: manual and automatic autoinjectors. The medicine delivery methods and user experiences provided by these sectors vary. With manual autoinjectors, the user must manually apply pressure or force to initiate the injection. To release the drug, the user usually needs to click a button or press the gadget against their skin. When the device is pressed against the skin and a safety mechanism is triggered, automatic autoinjectors are made to automatically trigger and administer the injection. Usually, a trigger or button is used for this, and it starts the injection process without requiring extra force or user pressure.

“Rheumatoid arthritis segment, by therapy, to be largest market from 2023 to 2030.”

The therapy segment of the global autoinjectors market comprise of rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis and others. Because rheumatoid arthritis is becoming more common, the category is expected to lead the market in terms of revenue throughout the forecast period. About 1% of people worldwide suffer from rheumatoid arthritis, which is the most prevalent kind of autoimmune arthritis. Approximately 1.3 million Americans—between 0.6% and 1% of the population—are afflicted with RA. The Arthritis Foundation (AF) estimates that between 0.5% and 1% of people in affluent nations worldwide have RA. In addition, a 2020 study found that the prevalence of RA varied throughout the Middle East and Africa, from 0.06% to 3.4%. Women are disproportionately affected by RA; over 75% of RA patients are female.

“Subcutaneous segment, by route of administration, to be largest market from 2023 to 2030.”

The segmentation of the autoinjectors market into subcutaneous and intramuscular categories is based on the different methods of delivering medications into the body, specifically regarding the depth and location of the injection site. The purpose of subcutaneous autoinjectors is to administer medicine into the tissue layer just under the skin. Because of its abundance of blood arteries, this layer enables the injected drug to be absorbed rather quickly. Mostly, they are applied to drugs that are readily absorbed through subcutaneous tissue. These injections are appropriate for people who might choose a less intrusive injection technique because they are frequently administered at a shallower depth than intramuscular injections.

“North America to be largest region in Autoinjectors Market.”

Over the course of the projection period, the North American market is expected to generate the greatest share of revenue. This is explained by continuing technological developments in medical equipment, an increase in the number of people suffering from diabetes and allergy, and supportive government regulations. For instance, Jabil Healthcare unveiled the Qfinity autoinjector technology on June 15, 2022, which is a reusable and modular platform for Subcutaneous (SC) self-administration. This innovation was made in response to the growing emphasis on sustainable drug delivery in the pharmaceutical business. Revenue growth in this region is also anticipated to be aided by the rising demand for home healthcare equipment and the robust presence of major industry competitors.

Autoinjectors Competitive Landscape

The competitive landscape of the Autoinjectors Market involves assessing the competitive landscape to understand the strengths, weaknesses, opportunities, and threats of the industry. Key industry players have recognized that the adoption of Autoinjectors technology holds the potential for further growth. The growing desire among producers to optimize their production costs has spurred collaborative efforts among companies to scale up their production capacity. This strategic collaboration not only aims to increase revenue but also seeks to establish dominance in the market.

The Autoinjectors Market is highly competitive, with numerous companies vying for market share. Prominent companies in the Autoinjectors Market include:

Major Players:

AbbVie Inc

Mylan N.V.

Lily, Amgen Inc.

Ypsomed Holding

BD

Owen Mumford Ltd.

Consort Medical, Plc

SHL Medical AG

Johnson Medtech, LLC

Teva Pharmaceuticals USA, Inc.

Recent Developments:

A new autoinjector platform for liquid medications with sizes ranging from 1.5 mL to 5.5 mL was introduced by Ypsomed on October 17, 2022. The newest product in the YpsoMate line allows patients to self-administer larger-volume medications, including those used to treat uncommon autoimmune illnesses and cancer.

Jabil Healthcare, a division of Jabil Inc., unveiled the Qfinity autoinjector platform in May 2022. When compared to other products on the market, this simple, reusable, and modular solution for self-administration of subcutaneous (SC) medications is more reasonably priced.

For the marketing of the Aidaptus auto-injector, Stevanato Group S.p.A. and Owen Mumford Ltd., a well-known medical device inventor and manufacturer, entered into an exclusive partnership in May 2022.

A division of Owen Mumford, Owen Mumford Pharmaceutical Services, successfully completed the development of its ground-breaking Aidaptus auto-injector platform on September 21, 2021. Aidaptus was developed to mitigate the risks associated with drug development and lifecycle management by addressing concerns pertaining to modifications in medication composition or injected volume.